10/13/2025
Research Article
Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study
In this phase 3, randomized, active-controlled study, Fumihiko Takeshita and colleagues assess the non-inferiority of COVID-19 vaccine DS-5670d compared to BNT162b2, as well as its safety profile.
Image credit: pixabay, handglove
Connect with Us